¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ

ÀϹݿ¬Á¦ ¹ßÇ¥ À¯ÀÇ»çÇ×

ÀϹݿ¬Á¦ ¹ßÇ¥ÀÚ´Â ¹Ýµå½Ã ¹ßÇ¥ ½½¶óÀ̵å(ÆÄ¿öÆ÷ÀÎÆ®)¸¦ »çÀü¿¡ Á¦ÃâÇÏ¼Å¾ß ¹ßÇ¥°¡ °¡´ÉÇÕ´Ï´Ù.
½½¶óÀ̵带 ±âÇÑ ³»¿¡ Á¦ÃâÇÏÁö ¾ÊÀ» °æ¿ì¿¡´Â ¹ßÇ¥ºÒ°¡´ÉÀ¸·Î °£ÁÖÇÕ´Ï´Ù.
¹ßÇ¥ ½½¶óÀ̵å¼ö´Â 15¸Å À̳»·Î 1Àå ´ç 10ÁÙ À̳»·Î Á¦ÀÛÇϽô °ÍÀ» ±ÇÀåÇϸç, ÁöÁ¤µÈ ¹ßÇ¥½Ã°£(7ºÐ ¹ßÇ¥-3ºÐ ÁúÀÇÀÀ´ä) À» Á¤È®È÷ ÁöÄÑÁֽñ⠹ٶø´Ï´Ù.

1. ÆÄÀÏ Á¦Ã⸶°¨ÀÏ : 9¿ù 17ÀÏ (¸ñ)
2. ÆÄÀÏ ÇüÅ : ÆÄ¿öÆ÷ÀÎÆ®
3. Á¦Ãâ ¹æ¹ý : ppt1@ksog.org


±¸¿¬ - Àüü   /    ¸ðüžÆÀÇÇР  /    ºÎÀÎÁ¾¾çÇР  /    »ý½Ä³»ºÐºñÇР  /    ÀϹݺÎÀΰúÇÐ

[ ±¸¿¬ - ºÎÀÎÁ¾¾çÇÐ ]

½Ã°£ ¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
ÁÂÀå : ±è¿µÅÂ(¿¬¼¼ÀÇ´ë)
13:00~13:40 GO1 Á¤¿ë¿í ¿¬¼¼ÀÇ´ë Robot-assisted staging using three robotic arms for endometrial cancer: Comparison to laparoscopy and laparotomy at a single institution
GO2 ½Å¼ÒÁø °è¸íÀÇ´ë Regulatory Role of Osteopontin in Malignant Transformation of Endometrial Cancer
GO3 µ¿¼­¿¬ °æÈñÀÇ´ë Association of the hSRBC gene polymorphism with endometrial cancer
GO4 Á¤±Ù¿À °æºÏÀÇ´ë Role of FDG PET in detecting myometrial invasion in patients with clinical stage I endometrial cancer
ÁÂÀå : ¹è´ö¼ö(¼º±Õ°üÀÇ´ë)
13:40~14:20 GO5 ³²ÁÖÇö ¿ï»êÀÇ´ë The integration of aggressive surgical procedures to achieve optimal cytoreduction improves the survival of patients with FIGO stage IIIC-IV epithelial ovarian cancer
GO6 ¹éÁöÈì ¿¬¼¼ÀÇ´ë Utility of HE4 and CA125 as multiple serum tumor markers for the prediction of ovarian cancer
GO7 Á¶ÇѺ° ¿¬¼¼ÀÇ´ë Gene and protein expression profiling of newly established ovarian cancer cell lines: Identification of TOM40 and NP for ovarian cancer diagnosis and therapy
GO8 ÀÌÈñÁØ ¼­¿ïÀÇ´ë Oxaliplatin, Leucovorin and 5-fluorouracil (FOLFOX-4) in Refractory Epithelial Ovarian Cancer: A Single Institutional Experience, 2002-2009
ÁÂÀå : ±è½Âö(ÀÌÈ­ÀÇ´ë)
14:20~15:00 GO9 À̽ÅÈ­ ¿ï»êÀÇ´ë Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix; a retrospective matched case-control study
GO10 À¯½Âö ¾ÆÁÖÀÇ´ë A validation study of new risk grouping criteria for tailoring postoperative adjuvant treatment in stage IB cervical cancer patients without high-risk factors: Rethinking the use of the GOG criteria
GO11 ±èÀ±È¯ ¼­¿ïÀÇ´ë Prognostic Significance of VEGF Polymorphisms in Early Cervical Cancer
GO12 À̼öÀ± ÀÌÈ­ÀÇ´ë Genetic polymorphism of ataxia telangiectasia mutated and cervical neoplasia risk in Korean women.
ÁÂÀå : ¹ÚÁø¿Ï(´Ü±¹ÀÇ´ë)
15:00~15:40 GO13 Àü¿µÀº ¿¬¼¼ÀÇ´ë Identification of STIP-1 as a Diagnostic and Therapeutic Biomarker Candidate for Ovarian Cancer by two-dimensional DITA (differential gel electrophoresis analysis of immunoprecipitated tumor antigens)
GO14 ±è±âÇü ºÎ»êÀÇ´ë The Antitumor activity and Molecular mechanism of novel isoflavone derivative NV-128 in Epithelial ovarian cancer cells
GO15 Á¶µ¿ÈÞ ÀüºÏÀÇ´ë Awareness of human papillomavirus among public health officials
GO16 Á¶Á¤¾Æ ¼º±Õ°üÀÇ´ë Tumor-derived exosomes can induce differentiation of mesenchymal stem cells into tumor-associated myofibroblastic cells
ÁÂÀå : ÃÖÈ£¼±(Àü³²ÀÇ´ë)
15:40~16:20 GO17 ÀÌÈ«ÁÖ ÇѾçÀÇ´ë Comparison of Mathematical Models to Detect Malignant pelvic masses in the preoperative evaluation
GO18 À̼ºÇÏ °¡Å縯ÀÇ´ë A clinicopathologic study in 1,042 patients with invasive cervical cancer: 10 years experience at the Department of Obstetrics and Gynecology of Kangnam St. Mary¡¯s hospital
GO19 À±¼®±Ù °üµ¿ÀÇ´ë Evaluation of prognostic factors and clinical outcomes in uterine sarcoma
GO20 ¼ÛÀçÀ± °í·ÁÀÇ´ë Body Mass Index change during Chemotherapy and prognosis in advanced ovarian cancer
ÁÂÀå : ³ëÈïÅÂ(Ãæ³²ÀÇ´ë)
16:20~17:00 GO21 ÀÌÀ¯¹Ì Â÷ÀÇ´ë Comparison of results of treatment of patients with GTN referred to a trophoblastic disease center after failure of treatment elsewhere and primarily treated at trophoblastic disease center
GO22 ¿À¹ÎÁ¤ Àü³²ÀÇ´ë Significance of Human Papillomavirus Genotyping with High-grade Cervical Intraepithelial Neoplasia Treated by a Loop Electrosurgical Excision Procedure
GO23 ±è±âµ¿ ¿øÀڷº´¿ø Risk factors for central failure in patients with locally advanced cervical cancer
GO24 ¼ÛÀº¼· ÀÎÇÏÀÇ´ë Clinical Analysis of Patients with of LSIL